| Methods |
Allocation concealment: NA
Blinding of study: no
Support: Pfizer (not apparent from the trial report, but from another report describing the same trial, see Discussion) |
| Participants |
502 participated total
Excluded: NA
Acute leukaemia, prophylactic |
| Interventions |
Fluconazole: 3 mg/kg/d orally
Amphotericin B: 25 mg/kg/d orally and/or nystatin 4 MIO IU orally |
| Outcomes |
Death
Infections
Dropouts because of adverse effects |
| Notes |
Follow‐up period (days): 6 weeks
Days on fluconazole: 27.8
Days on amphotericin B: NA
Support: Pfizer |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment (selection bias) |
Unclear risk |
B ‐ Unclear |
| Blinding (performance bias and detection bias)
All outcomes |
High risk |
|
